Xenetic Biosciences promote Jeffrey Eisenberg from board member to COO
pharmafile | December 5, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Xenetic
Xenetic Biosciences, a clinical-stage biopharmaceutical company, has announced the appointment of Jeffrey Eisenberg as chief operating officer.
Mr. Eisenberg has worked within the life sciences for over 20 years and has been on the board of directors, at Xenetic, since July 2016. Prior to joining the board at Xenetic, Mr. Eisenberg had over 17 years’ experience working various positions at Noven Pharmaceutical. He finally held the position of president and CEO before leaving. He had also experience working for Ivax Pharmaceuticals for three years.
“I am excited to join the Xenetic management team at such an important time in the Company’s evolution,” commented Mr. Eisenberg. “I believe Xenetic is poised to leverage its important partnership with Shire, advance its rich pipeline into late-stage clinical studies and further validate its technology platform in the near-term, all of which have the potential to build shareholder value. I look forward to playing a key role on the management team as we propel the Company towards its next phase of growth.”
“We are pleased to have Jeff increase his role with Xenetic and join the management team as Chief Operating Officer,” stated Scott Maguire, Xenetic’s chief executive officer. “I have full confidence his broad background, combined with his proven track record as a biopharma executive, will be invaluable to Xenetic, particularly our clinical timeline delivery. While I am very pleased with the tremendous progress we have made this year, we have an exciting road ahead, with much that still needs to be accomplished. I am confident that the Xenetic management team, especially with the addition of Jeff, is well positioned and prepared to advance our pipeline to bring much needed therapies to patients with unmet medical needs, and ultimately, unlock tremendous value for our shareholders.”
